O B J E C T I V E -D i e t a ry fiber has recently received recognition for reducing the risk of developing diabetes and heart disease. The implication is that it may have therapeutic benefit in prediabetic metabolic conditions. To test this hypothesis, we investigated the effect of supplementing a high-carbohydrate diet with fiber from Konjac-mannan (KJM) on metabolic cont rol in subjects with the insulin resistance syndro m e .
RESEARCH DESIGN AND METHODS
-We screened 278 free-living subjects between the ages of 45 and 65 years from the Canadian-Maltese Diabetes Study. A total of 11 (age 55 ± 4 years, BMI 28 ± 1.5 kg/m 2 ) were re c ruited who satisfied the inclusion criteria: i m p a i red glucose tolerance, reduced HDL cholesterol, elevated serum triglycerides, and moderate hypertension. After an 8-week baseline, they were randomly assigned to take either KJM fiber-enriched test biscuits (0.5 g of glucomannan per 100 kcal of dietary intake or 8-13 g/day) or wheat bran fiber (WB) control biscuits for two 3-week treatment periods separated by a 2-week washout. The diets were isoenergetic, metabolically controlled, and conformed to National Cholesterol Education Program Step 2 guidelines. Serum lipids, glycemic control, and blood pre s s u re were the outcome measure s .
Konjac-mannan and insulin resistance mannan (KJM) simultaneously impro v e d t h ree major CHD risk factors in type 2 diabetic subjects (17) .
In the present study, we tested the hypothesis that the same interv e n t i o n would improve the control of conventional and emerging CHD risk factors in pre d i abetic individuals with a full cluster of metabolic abnormalities that define the insulin resistance syndrome. KJM flour is obtained by grinding the tuber root of the A m o rphophallus Konjac C. Koch. plant and is traditionally used as a food and remedy in the Far East. In addition to our previous findings (17), other findings have shown it to i m p rove cholesterol levels (18,19), hypertension, and glycemia (20,21).
RESEARCH DESIGN AND M E T H O D S

Subjects
We screened 278 free-living subjects fro m the Canadian-Maltese Diabetes Study between the ages of 45 and 65 years. This population is known to have one of the highest rates of diabetes (22). Of the subjects, 38 satisfied the initial inclusion criteria: impaired glucose tolerance (IGT) (23); clinical absence of CHD; BMI 30 kg/m 2 ; not taking medications for hyperg l y c e m i a , hyperlipidemia or hypertension; not smoking; nor consuming more than two alcoholic drinks per day. These subjects were furt h e r s c reened for the presence of the full insulin resistance syndrome (2). This included moderate hypertension ( 135/85 and 145/95 mmHg), dyslipidemia (low HDL c h o l e s t e rol [ 0.9 mmol/l for men and 1 . 2 mmol/l for women], and elevated triglycerides [ 2.3 mmol/l and 4.5 mmol/l]). Based on power analysis from the pre v i o u s study (17), 11 subjects (5 men, 6 w o m e n ) who qualified were re c ruited. In addition to meeting the above criteria, their fasting (98 ± 13 pmol/l) and 2-h postprandial (439 ± 68 pmol/l) plasma insulin levels were g reater (P 0.05) than 2 SDs of the initial s c reening pool (71 ± 8 and 316 ± 47 pmol/l, respectively). All 11 also had moderately high serum cholesterol (5.2-6.7 mmol/l) and were sedentary, with a mean (± SD) age of 55 ± 4 years (range: 46-61); a BMI of 28 ± 3 kg/m 2 ; a waist-to-hip ratio of 0.98 ± 0.2 (waist: 96 ± 12 cm) in men and 0.91 ± 0.4 (waist: 87 ± 19 cm) in women. They gave written informed consent to participate in the current study that was approved by the Human Ethics Committees of St. Michael' s Hospital and the University of To ro n t o .
Study design
The study employed a double-blind p l a c e b o -c o n t rolled crossover design identical to that used on our previous study (17). It began with an 8-week baseline period during which participants followed a National Cholesterol Education Pro g r a m (NCEP) Step 2 (8) ad libitum diet, documented by three nonconsecutive days of food re c o rds every 2 weeks. This ru n -i n phase was included to eliminate possible e ffects of dietary change on metabolic parameters. The experimental phase of the study followed. This phase consisted of two successive 3-week treatment periods, separated by a 2-week washout interv a l over which a Step 2 diet was followed and documented by another 3-day food re c o rd . During the first treatment period, subjects w e re randomly assigned to either the KJM (Step 2 metabolically controlled diet enriched with KJM fiber) or the contro l t reatment (the same diet enriched with wheat bran [WB] fiber). For the second t reatment period, the subjects were cro s s e d o v e r. Blood collection, weight, blood pre ss u re, and waist and hip measure m e n t s w e re done at the beginning and end of each 3-week treatment period. The study began with five subjects taking the KJM t reatment and six the contro l .
Diet
Both treatments consisted of a 3-day ro t a ting Step 2 diet with three meals per day p rovided under metabolic conditions. All foods were pre-weighed, packaged, and d e l i v e red by courier to participants for consumption at home or at work. The mean m a c ronutrient profile closely conformed to a Step 2 diet ( 30% of calories from total fat, 7% from saturated fat, and 3 0 0 mg/day cholesterol) (8). Energ y intakes for weight maintenance were provided according to Lipid Research Clinics Tables with adjustment for physical activity (24). Total dietary fiber was administrated at 1.5 g/100 kcal, with a mean daily intake a c c o rding to energy intake ranging fro m 2 4 g to a plateau of 40 g for those consuming 2,800 kcal per day. The actual diet consumed is presented in Table 1 .
The two treatments diff e red only in the type of fiber. On the KJM treatment, part i cipants received KJM-enriched test biscuits, w h e reas on the WB-control treatment they received an equal quantity of WB contro l biscuits. Subjects were instructed to eat an equal amount of biscuits together with an 8-oz. beverage three times daily as a snack, including once at bedtime. Both were provided by Dicofarm S.p.A. (Rome). The biscuits had similar nutrient profiles and were indistinguishable in taste and appearance. KJM biscuits contained 10% KJM flour, of which 69% was the active high-viscosity glucomannan, 15% other polysaccharides, and 16% excipients by weight (17). Because KJM flour comprised half (0.75 g/100 kcal) of the total fiber on the KJM tre a t m e n t , 0.5 g/100 kcal (8-13 g/day) was glucomannan. WB biscuits, in contrast, had a lower pro p o rtion of total dietary fiber than KJM biscuits. There f o re, 11 g/day of wheat bran fiber derived from standard i z e d American Association of Cereal Chemists h a rd red wheat bran was, there f o re, added to the WB-control diet to compensate for these fiber diff e rences. Subjects were i n s t ructed to sprinkle the additional fiber on c e real, yogurt, and/or other compatible foods to improve the fiber' s palatability.
Any foods from the metabolic diet together with study biscuits not consumed during the study were re t u rned to the clinic for weighing to measure compliance. D i e t a ry changes found to occur during the first 3-week treatment period were duplicated in the diets for the second tre a t m e n t period for each part i c i p a n t .
Laboratory methods L a b o r a t o ry methods were identical to those used in our previous study (17). In brief, blood samples were separated immediately and stored as serum in four aliquots at 70°C after collection. They were thawed at the end of the study for analysis of total chol e s t e rol, HDL cholesterol, and triglycerides m e a s u red enzymatically. LDL cholestero l content was estimated by the formula of Friedewald et al. Apolipoprotein (apo) A1 and B were determined by rocket immunoe l e c t ro p h o resis. Fasting blood glucose was analyzed by a hexokinase method using a Cobas Mira Autoanalyzer (Roche Diagnostic, Mississauga, Canada). Serum fru c t o s a m i n e was analyzed in triplicate using Cobas Fara II and plasma insulin in duplicate by radioimmunoassay with reagent from ICN Biomedicals (Horsham, PA). C-peptide was d e t e rmined by radioimmunoassay.
Statistical analyses
Results are expressed as means ± SEM, except for age, anthropometric measurements, and nutrient intake (means ± SD). Data were analyzed by the Statistical Analysis System (SAS Institute, Cary, NC). Diff e rences between the diets were assessed by two-tailed Student' s t test for paired data (univariate pro c e d u re). This same statistic also assessed diff e rences in serum lipids, a p o l i p o p roteins, glycemia, blood pre s s u re , and body weight between the beginning (week 0) and end (week 3) of each tre a tment (WB-control and KJM). Analysis of covariance (ANCOVA) with general linear model (GLM) 25) . P values for each end point were ord e red sequentially and contrasted with the corre s p o n d i n g adjusted comparisonwise critical alpha ( ) levels. The null hypotheses were re j e c t e d only if P values were less than their corresponding v a l u e s . R E S U LT S -All participants followed the experimental protocol with little diff ic u l t y. Returned food from metabolic diets indicated that subjects consumed an average of 96% and 95% of diet calories prescribed on the KJM and WB-contro l t reatments, re s p e c t i v e l y. Returned biscuits indicated they consumed 81% (97 g/day) of KJM and 86% (103 g/day) of WB-cont ro l biscuits. Consumption patterns translated into an insignificant decrease in body weight during both treatment periods with no diff e rence between treatments (Table 2) . T h e only side effect experienced was a transient complaint of flatulence and soft stools re p o rted by three and two of the part i c ipants during the KJM and the WB-contro l t reatments, re s p e c t i v e l y, but none chose to discontinue the study.
Serum lipids
Blood lipids improved during KJM comp a red with WB-control treatment (Ta b l e2 ) . Total and LDL cholesterol fell significantly by 19 ± 2.7% (P 0.0001) and 29 ± 3.4% (P 0.0001) during KJM treatment comp a red with 6.3 ± 3.4% (P = 0.088) and 6.6 ± 5.0% (P = 0.231) on control tre a t m e n t . The between-treatment diff e rences were 12.4 ± 3.1% (P 0.005) and 22 ± 3.9% (P 0.003), re s p e c t i v e l y. The combined fall in total cholesterol from 6.2 ± 0.3 to 5.0 ± 0.2 mmol/l and LDL from 3.9 ± 0.2 to 2.8 ± 0.2 mmol/l on KJM treatment indicated reclassification of the lipid status of the g roup (8 of 11 subjects) from elevated to n o rmal cholesterolemia (7). Similar re s u l t s w e re observed for apo B. During KJM tre a tment, apo B fell significantly by 19 ± 2.8% (P 0.0004) compared to 4.5 ± 4.5% (P = 0.34) on control, for a significant diff e re n c e of 15.1 ± 4.3% (P 0.0004) between the t re a t m e n t s .
In contrast, such effects were not seen in apo A-1 or triglycerides. During KJM and c o n t rol treatments, HDL cholestero l d e c reased significantly on both tre a t m e n t s : 8.5 ± 2.2%, P 0.04 on KJM diet and 9.6 ± 2.2%, P 0.003 on WB-control, with an insignificant between-treatment change (P = 0.98). Similarly, during both tre a t m e n t s , triglycerides increased insignificantly, with no significant diff e rence between tre a t m e n t s .
Despite this lack of effect of KJM tre a tment on HDL cholesterol, apo A-1, or triglycerides, the decreases in total cholest e rol and apo B were sufficient to impro v e lipid ratios. During KJM tre a t m e n t , total/HDL, LDL/HDL, and apo B/A-1 ratios d e c reased by 11 ± 3.0% (P 0.005), 22 ± 3.7% (P 0.0002), and 13 ± 3.0% (P 0.003), re s p e c t i v e l y. This compares to an insignificant increase of 4.1 ± 4.1% in total/HDL ratio, 0.2 ± 6.3% in LDL/HDL ratio, and 0.7 ± 3.6 % in apo B/A-1 on W B -c o n t rol. The resulting between-tre a tment diff e rences were 15.2 ± 3.4% (P 0.003) for total/HDL cholesterol, 22.2 ± 4.1% (P 0.002) for LDL/HDL cholest e rol, and 13.1 ± 3.4% (P 0.0003) for apo B/A-1.
Glycemic control
An improvement in glycemic control was o b s e rved on the KJM compared with WBc o n t rol treatment (Table 2) . Serum fru ctosamine was reduced during the KJM t reatment by 5.6 ± 1.5% (P 0.003), comp a red with 0.39 ± 1.3% (P = 0.77) on cont rol treatment, with a between-tre a t m e n t d i ff e rence of 5.2 ± 1.4% (P 0.002). No significant between-treatment diff e re n c e s w e re seen for insulin or glucose concentrations. On KJM, however, fasting glycemia fell by 13 ± 2.5% (P 0.0001) compare d with 9.6 ± 4.3% (P 0.05) on contro l .
Blood pressure
No change in systolic or diastolic blood p re s s u re was observed on either tre a t m e n t or between treatments (Table 2) . All above results remained unchanged after adjustment for multiple comparisons by the Bonferro n i -H o c h b e rg pro c e d u re .
C O N C L U S I O N S -This pre l i m i n a ry study demonstrated that the addition of 0.5 g/100 kcal (8-13 g/day) of high-viscosity glucomannan in biscuit form to a high-carbohydrate/low-saturated fat NCEP
Step 2 diet improved metabolic contro l beyond diet alone in individuals with the insulin resistance syndrome. We observ e d significant reductions in hyperglycemia as DIABETES CARE, VOLUME 23, NUMBER 1, JANUARY 2000 11
Vuksan and Associates Table 1 -Average intake of energy and nutrients before and during study periods in 11 subjects P a r a m e t e r s B a s e l i n e K J M W B
Total energy (kcal/day) 2,070 ± 700 2,579 ± 628 2,355 ± 420 Total fat (% of energ y ) 30.5 ± 4.3 29.3 ± 3.2 28.7 ± 2.4 Saturated fat (% of energ y )
7.2 ± 4.7 6.7 ± 0.8 6.4 ± 0.7 Monounsaturated fat (% of energ y ) 10.3 ± 5.1 12.7 ± 2.1 12.2 ± 2.6 Polyunsaturated fat (% of energ y )
13.0 ± 5.7 9.9 ± 1.8 10.1 ± 0.9 C h o l e s t e rol (mg/day) 328 ± 102 219 ± 48 236 ± 77 Total protein (% of energ y )
14.6 ± 8.2 16.2 ± 2.7 15.6 ± 3.2 Available carbohydrate (% of energ y ) 54.9 ± 21 54.5 ± 9.4 55.7 ± 7.3 Sugars (% of energ y )
13.3 ± 3.6 11.2 ± 0.9 9.2 ± 1.4 Fiber (g/day)
To t a l 24.2 ± 11 34.7 ± 8.4 33.4 ± 9.6 Wa t e r-s o l u b l e 6.9 ± 3.2 23.4 ± 1.7 9.9 ± 3.2* Wa t e r-i n s o l u b l e 17. m e a s u red by the short -t e rm marker of glycemic control, fructosamine, although the clinical significance of the observ e d changes remains to be demonstrated. We also observed significant reductions in hyperlipidemia as measured by total, LDL, LDL/HDL, and total/HDL cholesterol, and apo B and apo B/A-1, relative to a matched W B -c o n t rol treatment. These findings re present the first to demonstrate such i m p rovements using soluble fiber in subjects with this particular cluster of risk factors that also includes the interm e d i a t e diabetic classification, IGT. Because of the strong implications of insulin resistance syndrome, a more aggre ssive approach has been suggested to achieve similar reductions. Diabetes and heart disease share common precursors for the development of athero s c l e rosis that often c o -o c c u r. Long before diabetes becomes manifest, the clustering of metabolic abnormalities exerts a synergistic effect on the athe ro s c l e rotic process (26). Based on findings f rom Trevisea and colleagues, card i o v a s c ular disease (CVD) risk appears to incre a s e linearly with an increase in the number of these risk factors. It is recommended theref o re that insulin-resistant patients have their CHD risk factors managed as if they have established CHD (27).
Low-fat/high-carbohydrate diets may still have promise as a therapeutic appro a c h . Although there has been a shift away fro m their advocacy in favor of those rich in monounsaturated fat (8), these diets supplemented with fiber may have similar metabolic advantages. Guar gum, pectin, oat p roducts, and psyllium added to high-carbohydrate diets have been shown to i m p rove total and LDL cholesterol signific a n t l y, with no improvement to triglycerides and slight or no adverse effects on HDL (16). Both guar (14) and KJM (17,18) supplementation have also been shown to i m p rove other risk factors, including glycemia and blood pre s s u re. This has led to s u p p o rt for the use of guar in the tre a t m e n t of the insulin resistance syndrome (13). Evidence further suggests that supplementation with these soluble fibers may augment c o n c u rrent drug therapy. Improvements in these assorted risk factors following supplementation have been noticed beyond what was achieved by drugs alone in subjects receiving hypolipidemic (14,17,28), hypoglycemic (14,17,29), and hypotensive (17,30) medications.
The ability of soluble fiber to impro v e a high-carbohydrate/low-fat diet is supp o rted by the findings of the present study. Total and LDL cholesterol were decre a s e d and glycemic control was improved signific a n t l y. Also, although HDL, apo A-1, and triglycerides were unaffected, as has been noticed with other fibers, this was balanced by the significant improvements in the other lipid end points, leading to significant reductions in all three lipid ratios: total/HDL, LDL/HDL, and apo B/A-1. Similar improvements in these ratios have r a rely been re p o rted using dietary interventions (28,29). Overall, the suggestion is that an NCEP Step 2 diet supplemented with KJM may confer additional benefits over the Step 2 diet alone, benefits that may be comparable to strategies using monounsaturated fat.
KJM may be better suited than the other major soluble fibers to improving outcomes with high-carbohydrate/low-fat diets. Although meta-analyses use varianceadjusted values that tend to undere s t i m a t e e ffectiveness, KJM can be compared to other soluble fibers in terms of its lipid-lowering ability per gram of fiber, using recent metaanalytical data (15). Daily intake of glu-
